Dueling Court Rulings Put State of Mifepristone in Limbo

Access to the abortion pill mifepristone is in limbo following two contradictory court rulings. On April 7, U.S. District Judge Matthew Kacsmaryk ordered the FDA to suspend its approval of mifepristone, which the agency first issued in 2000. The judge gave the Biden administration seven days to appeal.

On April 10, the Dept. of Justice asked the 5th U.S. Circuit Court of Appeals to block the ruling and keep the drug on the market as litigation plays out. On April 12, the court ruled that mifepristone will remain available for now but with new restrictions, including a requirement for in-person doctor visits to obtain the drug. The Biden administration then responded that it would immediately seek emergency relief from the Supreme Court to restore full access to mifepristone.

Meanwhile, states including New York, Massachusetts, California and Washington are rushing to stockpile abortion pills.

© 2024 MMIT
Jinghong Chen

Jinghong Chen Reporter

Jinghong produces infographics and data stories on health insurance and specialty pharmacy for AIS Health. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting. Before joining AIS in 2018, she worked at WBEZ, Al Jazeera English and The New York Times Chinese.

Related Posts

pharmacists
November 4

House Committee Calls Out Birth Control Coverage Barriers; Insurers Hit Back

READ MORE
pharmacist-with-medications
July 28

Medication Abortion Faces Legal Uncertainty Post-Dobbs

READ MORE
a-patient-taking-pills
July 1

Fewer Abortion Facilities Accept Health Insurance, While Patients Face Higher Out-of-Pocket Expenses for Abortion

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today